EyeCRO scientists contribute to paper published in Biology
Therapeutic Effects of Fenofibrate Nano-Emulsion Eye Drops on Retinal Vascular Leakage and Neovascularization
Similar Posts
New Trial Shows Drugs are Effective for Diabetic Macular Edema
Diabetes is a significant risk factor for developing eye diseases. The most common diabetic eye disease and a leading cause of blindness is diabetic retinopathy. Americans with diabetic retinopathy have diabetic macular edema (DME) in which fluid leaks into the macula, the area of the retina used when looking straight ahead. Over the past few…
Spark Surges in IPO as Prices Fuel Gene Therapy
Spark Therapeutics Inc. hit a $1.2 billion valuation on the biotechnology firm’s first day on the market, reflecting growing investor enthusiasm for the once-beleaguered field of gene therapy, a field that has produced the first $1 million drug. The treatments focus on diseases where a single mutation in the genetic code is known to be…
Patient-reported outcomes and visual acuity after 12 months of anti-VEGF-treatment for sight-threatening diabetic macular edema in a real world setting
This study was an evaluation, at 12 months follow-up, of anti VEGF treatment for diabetic macular edema conducted in a real world setting. To examine objective visual acuity measured with ETDRS, retinal thickness (OCT), patient reported outcome and describe levels of glycated hemoglobin and its association with the effects on visual acuity in patients treated…
EyeCRO conducts successful pre-IND meeting with US Food and Drug Administration to discuss CsA-MIDROPS™
EyeCRO recently requested and conducted a pre-IND meeting with the US FDA to discuss the nonclinical and clinical development plans for CsA-MiDROPS™ to treat Dry Eye Disease. The agency was supportive of the project and agreed that the proposed nonclinical and CMC studies would allow entry into a phase II clinical trial. Also discussed was…
RetroSense Granted Orphan Drug Designation for Retinitis Pigmentosa
RetroSense Therapeutics, LLC, a privately-held biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for the Company’s lead product RST-001 for the treatment of retinitis pigmentosa (RP). Retinitis pigmentosa is a genetic condition which leads to the progressive degeneration of rod and cone photoreceptors (cells found in…
Smartphones become ‘eye-phones’ with low-cost devices developed by ophthalmologists
Researchers at the Stanford University School of Medicine have developed two inexpensive adapters that enable a smartphone to capture high-quality images of the front and back of the eye. The adapters make it easy for anyone with minimal training to take a picture of the eye and share it securely with other health practitioners or…